Congratulations to Elizabeth Alessi, our vice president of regulatory affairs, medical writing, and pharmacovigilance, on her appointment as an alternate to the non-voting industry representative on the FDA Genetic Metabolic Diseases Advisory Committee. Elizabeth is an invaluable member of our team, and we know she will make an impact on this committee reviewing the safety and effectiveness of investigational drugs used in the treatment of genetic metabolic diseases.
About us
We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
- Website
-
http://www.inozyme.com
External link for Inozyme Pharma
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
321 Summer St
Suite 400
Boston, Massachusetts 02210, US
Employees at Inozyme Pharma
Updates
-
We are looking forward to attending the 2024 Wedbush Securities PacGrow Healthcare Conference today in New York. Our CEO and Chairman, Doug Treco, Ph.D., will participate in a panel discussion on “Hunting the Last Unicorns: Rare Diseases” this afternoon at 2:30 p.m. ET. #RareDisease #Biotech #Biopharmaceutical
-
Today, we reported Q2 2024 earnings and business highlights. We continue to advance our lead candidate, INZ-701, toward several clinical milestones and have made strides with regulators, including a Fast Track designation from the FDA in our ABBC6 Deficiency program. We look forward to reporting progress through the end of the year for our #ABCC6 Deficiency, #ENPP1 Deficiency and #Calciphylaxis programs. Learn more: https://bit.ly/3WTqC9M #RareDisease #Biotech #Biopharmaceutical
-
On National Intern Day today, we recognize our interns for their contributions throughout this summer. We celebrate their talent and shared dedication to restoring health and hope to patients with #RareDiseases. We're excited to see what their futures hold! #NationalInternDay
-
Data published in a recent article in the Cells scientific journal supports the potential of our lead candidate, INZ-701, to treat a broad range of #RareDiseases that affect bone health and blood vessel function mediated by the PPi-Adenosine Pathway. Read the full news release here: https://bit.ly/3zXfBLv
-
We are thrilled to announce the launch of Inozyme’s new website! This milestone enhances our online presence, making it easier for patients, healthcare professionals, and key audiences to access vital information about our mission and work. Our new site reflects our commitment to innovation and patient care, offering a fresh look, improved navigation, and comprehensive content about our research, INZ-701, and the PPi-Adenosine Pathway. Explore the new website to learn more about our dedication to advancing therapeutics for rare diseases impacting bone health and blood vessel function. Visit now: https://www.inozyme.com/
-
We are proud to share a thought-provoking op-ed by our COO, Matt Winton, Ph.D., in BioSpace. In this article, he discusses the critical need for Congress to reauthorize the FDA’s Priority Review Voucher (PRV) program. This program is crucial for advancing the development of life-saving treatments for children suffering from rare diseases. The reauthorization will ensure continued support for innovative research and drug development, directly impacting the lives of our youngest and most vulnerable patients. At Inozyme, we are committed to addressing the unmet needs of patients with rare diseases, and this op-ed highlights the importance of sustained legislative support in achieving our mission. The FDA's pediatric rare disease program has been instrumental in bringing new therapies to market, offering hope and improved outcomes for countless families. Matt joined other biopharmaceutical leaders last week in Washington, D.C., as part of a delegation of The Rare Disease Company Coalition to discuss the PRV program's impact on drug development for pediatric rare diseases Join us in advocating for this vital initiative by reading the full article and learning more about the impact and significance of this program. Together, we can make a difference in the lives of children with #RareDiseases. Read the full article: https://bit.ly/3zA36oP #PriorityReviewVoucher #Biotech #Biopharmaceutical
-
Inozyme Pharma reposted this
We were honored to join Senator Amy Klobuchar today to discuss the best ways to support the millions of Americans living with the #raredisease - including the reauthorization of the #PriorityReviewVoucher program. We are so thankful to the Senator for her commitment to the rare disease community, including her leadership in the Rare Disease Caucus. Thanks for your time today, Senator! Reenie McCarthy, Rebecca Michalski McLeod, Adora Ndu, Steven Pfanstiel, Stuart Siedman, Izabella (Izzy) Tyszler, Matt Winton, Stacey Frisk
-
Our Women in Progress (WIP) team recently hosted an informative seminar led by Brad Johnson and David Smith, co-authors of the acclaimed book "Good Guys: How Men Can Be Better Allies for Women in the Workplace." The interactive session delved into practical strategies for creating a more inclusive work environment through the power of effective allyship. Attendees actively participated by applying these concepts to scenarios specific to Inozyme, generating lively discussions. We left the event well-equipped with valuable tools and a renewed perspective to promote a more equitable workplace for all. #InozymeWIP #Allyship #WorkplaceInclusion
-
We are proud to share this published article from our colleagues, which highlights how INZ-701 can prevent intimal proliferation (excessive cell growth within blood vessel walls). This overgrowth can obstruct blood flow and increase the risk of cardiovascular events like heart attacks and strokes. The research broadens potential therapeutic applications of INZ-701 beyond enzyme replacement therapy in our three ongoing clinical programs in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, where morbidity and mortality can be driven by intimal proliferation. Read the research here: https://bit.ly/3XRS4W6
Proud to share our latest publication highlighting how INZ-701 (ENPP1-Fc) can prevent intimal proliferation in both ENPP1 deficient mice (GACI/ARHR2) as well as in WT mice in a carotid ligation mouse model of intimal proliferation. Striving to advance research and bring transformative therapies to our patients #intimalproliferation #GACI #ARHR2